eagle-i University of PennsylvaniaUniversity of Pennsylvania
See it in Search

Preclinical Models Core

Directors: French, Deborah L., PhD; Grinspan, Judith., PhD; Zhou, Zhaolan (Joe)., PhD

Summary:

The Preclinical Models Core (PMC) was developed in response to a user survey that emphasized a need for an IDD-focused facility for the study of mammalian behavior and one to address the potential of current stem cell technologies, including genome editing using CRISPR-Cas9.

Affiliations:

People:

Resources:

Services

  • Behavioral Testing Service ( Support service )

    -- Customized Behavior Battery Design
    -- Consultation in experimental design and interpretation of results
    -- Tests of learning and memory, affective disorder-related behaviors, social and communication tasks, neurodegeneration and sensation
    -- Protocol and Transfer Assistance (IACUC, ULAR, and LAR)
    -- Training in all Procedures
    -- Drug delivery
    -- Tissue harvest
    -- Video image analysis
    -- Data Analysis

  • Human Pluripotent Stem Cell (PSC) Service ( Support service )

    1) Generate and characterize iPSCs
    Make them available to the research community

    2) Differentiate PSCs
    Mesodermal, endodermal, ectodermal lineages

    3) Genetically manipulate PSCs
    Transgene expression: Zinc finger nucleases

    4) Gene editing PSCs
    Gene loci: CRISPR/Cas9

    5) Distribute NIH-approved human ESC lines

    6) Distribute quality tested specialty reagents

    7) Enrichment training

  • Tissue Culture and Antibody Service ( Support service )

    1) Generation of a variety of cell culture models:
    a) Primary cultures of neurons, astrocytes, microglia and oligodendrocytes
    b) Co-cultures of specific cell types
    c) Organotypic cultures

    2) Culture maintenance and use:
    a) Propagation, amplification and cryopreservation of these cultures.
    b) Variety of purification methods: immunopanning, "shake-off", Macs manual cell sorting
    c) Evaluation of other culture and cell separation methods such as adult neural tissue cell separator (coming soon).
    d) After exposure to agents: monitoring of cell death, toxicity, proliferation, differentiation, morphological alterations

    3) Antibody services:
    a) Validation and use of specific antibodies for neural cells


Web Links:

Last updated: 2019-12-10T14:52:41.781-05:00

Copyright © 2016 by the President and Fellows of Harvard College
The eagle-i Consortium is supported by NIH Grant #5U24RR029825-02 / Copyright 2016